Cerecero-García Diego, Terris-Prestholt Fern, Macías-González Fernando, Bautista-Arredondo Sergio
Public Health Policy Evaluation Unit Imperial College London England Public Health Policy Evaluation Unit, Imperial College, London, England.
United Nations Joint Programme on HIV/AIDS Geneva Switzerland United Nations Joint Programme on HIV/AIDS, Geneva, Switzerland.
Rev Panam Salud Publica. 2024 Sep 16;48:e84. doi: 10.26633/RPSP.2024.84. eCollection 2024.
To summarize available data on unit costs for human immunodeficiency virus (HIV) testing, prevention, and care interventions in Latin America and the Caribbean.
We conducted a systematic literature review of costing studies published between 2012 and 2024, and selected those reporting empirically measured costing data. The available data were categorized according to predefined intervention categories and compared by time and place. We also explored variations in unit costs by intervention type.
Of 1 746 studies identified, 22 met the inclusion criteria, which provided 103 unique unit cost estimates from nine countries. About 50% of the included studies were published between 2019 and 2021. Antiretroviral therapy services had the most cost data available (39% of unit costs), followed by inpatient care (27%) and HIV testing (24%). Considerable cost variations were observed both within and between interventions.
Our analysis underscores the need for accurate and reliable cost data to support HIV budgeting and decision-making efforts. We identified several gaps in the availability of cost data and emphasize the importance of presenting results more effectively by incorporating key contextual variables. Given the challenges of shrinking budgets and sustainability risks, robust evidence is indispensable to inform priority setting and budget allocation for HIV services.
总结拉丁美洲和加勒比地区人类免疫缺陷病毒(HIV)检测、预防及护理干预措施单位成本的现有数据。
我们对2012年至2024年间发表的成本核算研究进行了系统的文献综述,并选取了那些报告了实证测量成本数据的研究。现有数据根据预定义的干预类别进行分类,并按时间和地点进行比较。我们还探讨了不同干预类型的单位成本差异。
在检索到的1746项研究中,22项符合纳入标准,这些研究提供了来自9个国家的103个独特的单位成本估计值。约50%的纳入研究发表于2019年至2021年之间。抗逆转录病毒治疗服务的成本数据最多(占单位成本的39%),其次是住院护理(27%)和HIV检测(24%)。在干预措施内部和之间均观察到了相当大的成本差异。
我们的分析强调了需要准确可靠的成本数据来支持HIV预算编制和决策工作。我们发现了成本数据可用性方面的几个差距,并强调了通过纳入关键背景变量更有效地呈现结果的重要性。鉴于预算缩减和可持续性风险的挑战,有力的证据对于为HIV服务确定优先事项和分配预算至关重要。